Integra LifeSciences
IART
225 hedge funds and large institutions have $1.24B invested in Integra LifeSciences in 2024 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 62 increasing their positions, 84 reducing their positions, and 63 closing their positions.
2,639% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $388K
0.66% more ownership
Funds ownership: 90.03% → 90.69% (+0.66%)
5% less funds holding
Funds holding: 238 → 225 (-13)
21% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 63
26% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 84
40% less capital invested
Capital invested by funds: $2.07B → $1.24B (-$823M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHCM
Sachem Head Capital Management
New York
|
+$56.3M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$49.3M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$46.4M |
| 4 |
Goldman Sachs
New York
|
+$16.3M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CB
Cooke & Bieler
Philadelphia,
Pennsylvania
|
-$102M |
| 2 |
DM
Deerfield Management
New York
|
-$42.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$39M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$26.1M |
| 5 |
PE
Point72 Europe
London,
United Kingdom
|
-$15.9M |
IART Hedge Fund Activity: Q3 2024 in Review
225 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2024, worth a combined $1.24B — down 40% from $2.07B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of IART and 50 opened new positions — a net loss of 13 holders — while 84 trimmed existing stakes and 62 added.
The largest buyer was Sachem Head Capital Management, opening a new position worth an estimated $56.3M. The largest seller was Cooke & Bieler, exiting entirely with an estimated $102M sold.
- 225 institutional investors held Integra LifeSciences (IART) as of Q3 2024, down from 238 in Q2 2024.
- Funds reported $1.24B of Integra LifeSciences stock for Q3 2024, down 40% quarter-over-quarter.
- 50 funds opened new Integra LifeSciences positions in Q3 2024 and 63 closed out, a net change of -13 holders.
- The largest Integra LifeSciences buyer in Q3 2024 was Sachem Head Capital Management, an estimated $56.3M added.
- The largest Integra LifeSciences seller in Q3 2024 was Cooke & Bieler, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2024.